Company Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems.
The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products.
The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
| Country | United States |
| Founded | 1897 |
| IPO Date | Apr 23, 1962 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 73,000 |
| CEO | Thomas E. Polen Jr. |
Contact Details
Address: One Becton Dr Franklin Lakes, New Jersey 07417-1880 United States | |
| Phone | (201) 847-6800 |
| Website | bd.com |
Stock Details
| Ticker Symbol | BDX |
| Exchange | NYSE |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000010795 |
| CUSIP Number | 075887109 |
| ISIN Number | US0758871091 |
| Employer ID | 22-0760120 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Thomas E. Polen Jr. | President, Chief Executive Officer and Chairman |
| Christopher J. DelOrefice | Executive Vice President and Chief Financial Officer |
| Shana Carol Neal | Executive Vice President and Chief People Officer |
| David B. Hickey | Executive Vice President and President of Life Sciences Segment |
| Michael Garrison | Executive Vice President and President of Medical segment |
| Thomas J. Spoerel | Senior Vice President, Controller and Chief Accounting Officer |
| Elizabeth McCombs | Executive Vice President and Chief Technology Officer |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior Vice President, Chief Scientific Officer and Co-Chair of Scientific Advisory Board |
| Denise Russell Fleming | Executive Vice President of Technology and Global Services and Chief Information Officer |
| Greg Rodetis | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2024 | 144 | Filing |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | CERT | Certification by an exchange approving securities for listing |
| Feb 9, 2024 | 8-A12B | Registration of securities |
| Feb 8, 2024 | 8-K | Current Report |
| Feb 7, 2024 | 424B2 | Prospectus |
| Feb 7, 2024 | 424B2 | Prospectus |